FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-0287									
	Estimated average b	ourden									
1	haura nar raananaa	٥٦									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BELANOFF JOSEPH K				2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]								(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
	RCEPT TH	irst) (ERAPEUTICS D ROAD, SUITE	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 08/10/2005							X	belov	er (give title w) Chief Exe		below	(specify)	
(Street) MENLO (City)	PARK C		94025 Zip)		4. If	Amer	ndment	, Date o	of Origin	ginal Filed (Month/Day/Year)					Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			Date	(Month/Day/Year) if any		cution	ution Date,		ction Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		and 5) Securit Benefic Owned		ies ially Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Pric	e	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock 08/10/			08/10/2	2005	005		S ⁽¹⁾		762	D	\$5.	7508	2,31	13,433		D			
Common Stock														300	0,000		I	Custodian for minor son ⁽²⁾	
Common Stock													300	0,000		I	Custodian for a minor daughter ⁽²⁾		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction (Month/Day/Year)					6. Date Exerci Expiration Dat (Month/Day/Ye		ite	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (In	Price of crivative ccurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
Code		Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Numb of Shares									

Explanation of Responses:

- $1. \ The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.$
- 2. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.

Remarks:

s/s Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

08/11/2005

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.